Indication

Neuromyelitis optica spectrum disorder with anti-aquaporin-4 (AQP4) antibodies

Neuromyelitis optica spectrum disorder with anti-aquaporin-4 (AQP4) antibodies is a severe, relapsing autoimmune astrocytopathy of the central nervous system that predominantly targets the optic nerves, spinal cord, and brainstem. Read more about Neuromyelitis optica spectrum disorder with anti-aquaporin-4 (AQP4) antibodies

5 drugs 4 manufacturers

Advertisement

Drugs that treat it

Common Neuromyelitis optica spectrum disorder with anti-aquaporin-4 (AQP4) antibodies therapies.

Showing 1–5 of 5 drugs

UPLIZNA (inebilizumab-cdon)

ANTINEOPLASTIC MONOCLONAL ANTIBODIES·NEUROMYELITIS OPTICA SPECTRUM DISORDER WITH ANTI-AQUAPORIN-4 (AQP4) ANTIBODIES·+3
HORIZON/AMGEN
Filter & compare in the drug finder →Opens the drug finder with Neuromyelitis optica spectrum disorder with anti-aquaporin-4 (AQP4) antibodies preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Neuromyelitis optica spectrum disorder with anti-aquaporin-4 (AQP4) antibodies.

Neuromyelitis optica spectrum disorder with anti-aquaporin-4 (AQP4) antibodies is a severe, relapsing autoimmune astrocytopathy of the central nervous system that predominantly targets the optic nerves, spinal cord, and brainstem.

Pathophysiologically, circulating immunoglobulin G autoantibodies bind to aquaporin-4 water channels on astrocyte end-feet, triggering complement-mediated inflammation, secondary demyelination, and neuronal death.

Clinically, affected individuals experience recurrent neuroinflammatory attacks characterized by severe optic neuritis, longitudinally extensive transverse myelitis, and area postrema syndrome presenting with intractable nausea and hiccups, which frequently lead to cumulative, permanent visual and motor disabilities.

Personalize your experience

Follow Neuromyelitis optica spectrum disorder with anti-aquaporin-4 (AQP4) antibodies and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it